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Summary 
Gastric cancer (GC) is still one of the prevalent leading causes of cancer-
related deaths worldwide and high mortality rate is mainly due to late-
stage diagnosis. GC is characterized by two distinct histological type of 
adenocarcinomas each having different epidemiological and 
pathophysiological features. The intestinal-type generally evolves through 
a relatively well-defined sequence of histological lesions. The diffuse-
type has instead a poorer prognosis and develops through unknown 
genetic and morphological events from normal gastric epithelium. The 
pathogenesis of GC remains poorly understood however several 
environmental factors, such as Helicobacter pylori (H. pylori) infection 
can be the cause leading to this disease. This risk is probably the result of 
a combination of genetic and environmental factors in which the infection 
by H. pylori is of particular relevance. To search for gastric cancer 
biomarkers, we have analyzed the protein profile of malignant and normal 
gastric tissues and identified a novel stomach specific protein gastrokine 1 
(GKN1) whose expression is reduced in H. pylori infected gastric mucosa 
and down-regulated or completely absent in GC tissues and precancerous 
lesions so this protein might play an important role as biomarker in 
carcinogenic process. On the basis of these evidences, we are 
investigating on the possible utility of GKN1 as an informative 
biomarker. To do this, we have analyzed by Western blot the expression 
profile of GKN1 in several biological fluids of normal individual in order 
to highlight the presence of GKN1 at the protein level. However, no 
GKN1 expression was possible to detect even if the search was performed 
by ELISA assay on serum of healthy individuals. We then have searched 
for the presence of GKN1 mRNA in the serum of healthy subjects by RT-
PCR using several primers spanning over the entire GKN1 cDNA. This 
result suggests that qRT-PCR might be a possible media by which to 
follow the GKN1 expression profile in normal patients and in patients 
with gastric lesions in order to assess its possible use as preventive gastric 
cancer biomarker. The second part of my work is focused on 
identification of potential GKN1 interactors with the aim to add 
knowledge on its functional role within gastric cell lines and tissues. To 
this purpose we used a proteomic strategy and the GKN1 interactors were 
identified by peptide mass fingerprinting using MALDI-TOF mass 
spectrometry. The results show that GKN1 interacts whit SLC26A3, a 
protein expressed in apical membrane of intestinal epithelial cells. 
Therefore, we propose in future, the evalutation of SLC26A3 in human 
sera as a potential innovative biomarker in CG. 
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Riassunto 
Il cancro gastrico (GC) è ancora oggi in tutto il mondo una delle 
principali cause di decessi correlati al cancro, e l’alto tasso di mortalità è 
dovuto principalmente alla diagnosi in fase avanzata. Il GC è 
caratterizzato da due tipi istologici distinti di adenocarcinomi, ciascuno 
con caratteristiche epidemiologiche e fisiopatologiche differenti. Il tipo 
intestinale evolve generalmente attraverso una sequenza relativamente 
ben definita di lesioni istologiche. Il tipo diffuso ha invece una prognosi 
peggiore e si sviluppa dal normale epitelio gastrico attraverso eventi 
genetici e morfologici sconosciuti. La patogenesi della GC rimane poco 
compresa tuttavia diversi fattori ambientali, come l'Helicobacter pylori 
(H. pylori) rappresenta la principale causa della malattia. Questo rischio è 
probabilmente il risultato di una combinazione di fattori genetici e 
ambientali in cui l'infezione da H. pylori è di particolare rilevanza. Per 
ricercare biomarcatori del cancro gastrico, abbiamo analizzato il profilo 
proteico di tessuti gastrici maligni e normali. E’ stata individuata una 
proteina specifica dello stomaco, gastrokina 1 (GKN1), la cui espressione 
è ridotta nella mucosa gastrica con infezionw da H. pylori e down-
regolata o completamente assente in tessuti GC e lesioni precancerose. 
Pertanto GKN1 potrebbe svolgere un ruolo importante come biomarker 
nel processo di cancerogenesi. Sulla base di queste evidenze, e stata 
valutata la possibile utilità della GKN1 come biomarker informativo. A 
tale scopo, è stato analizzato mediante Western blot il profilo di 
espressione della GKN1 in diversi liquidi biologici di individui normali al 
fine di evidenziare la presenza della GKN1 a livello proteico. Tuttavia, 
nessuna espressione di GKN1 è stato possibile rilevare anche quando la 
ricerca è stata effettuata mediante saggio ELISA. E’ stato poi cercato di 
evidenziare la presenza dell’mRNA di GKN1 nel siero di soggetti sani 
mediante RT-PCR utilizzando diverse coppie di primers all’interno del 
cDNA di GKN1. Il risultato ottenuto ha evidenziato che la qRT-PCR 
potrebbe essere un possibile metodo per confrontare il profilo di 
espressione di GKN1 in pazienti normali e in pazienti con lesioni 
gastriche e quindi valutarne il possibile uso come biomarker cancro 
gastrico. La seconda parte della tesi si concentra sulla identificazione di 
potenziali interattori della GKN1, con l'obiettivo di aggiungere nuove 
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conoscenza sul ruolo funzionale della proteina in cellule e tessuti gastrici. 
A questo scopo è stata utilizzata una strategia proteomica e gli interattori 
della GKN1 sono stati identificati mediante MALDI-TOF. I risultati 
mostrano che GKN1 interagisce SLC26A3, una proteina espressa in 
membrana apicale delle cellule epiteliali intestinali. Pertanto, ci 
proponiamo in futuro, di valutare i livelli di espressione di SLC26A3 e di 
utilizzarlo come possibile innovativo biomarker del CG. 
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1. Introduction 
 
1.1 Gastric cancer 
Although the prevalence of gastric cancer is declining and varying 
geographically, it remains one of the most common cancers in Asian 
countries and is the fourth most commonly occurring cancer (9% of all 
cancers) worldwide. It is also the fourth leading cause of cancer death in 
both sexes worldwide (737,000 deaths, 9.7% of the total). Five-year 
survival rates have ranged from 90% to less than 5 percent, mainly 
depending on the stage of diagnosis. If gastric cancer can be detected and 
treated in early stages, the five-year survival rate is better than 90%; 
however, there is no apparent or specific symptom in early-stage gastric 
cancer. Thus, early detection of gastric cancer becomes more difficult. 
Essentially, endoscopy has been the promising tool with 2.7 to 4.6-times 
higher detection rate than barium studies. Early gastric cancer diagnosis 
by endoscopy depends on professional skill. However, there is no reliable 
biomarker for gastric cancer (Wu et al., 2014). 
Two distinct histological types of adenocarcinoma showing different 
epidemiological and pathophysiological features often characterize gastric 
cancer. The intestinal-type generally evolves through a relatively well-
defined sequence of histological lesions, namely nonatrophic gastritis, 
chronic atrophic gastritis, intestinal metaplasia, and dysplasia. The diffuse 
subtype has instead a poorer prognosis and develops from normal gastric 
epithelium through unknown genetic and morphological events. The 
pathogenesis remains poorly understood, but it’s evident that several 
environmental and infective factors, such as Helicobacter pylory 
infection, can be the leading cause to this disease. In fact H. pylory 
infection is associated with risk of gastric adenocarcinoma, both intestinal 
and diffuses type, supported by the link between this infection and 
precancerous lesions, including chronic atrophy gastritis and dysplasia. 
The positive correlation between H. pylory infection and development of 
gastric cancer is well established and proven in prospective controlled 
studies. Exposure of gastric epithelial cells to the bacterium determines 
the release of cytokines and reactive oxygen species (ROS) leading to the 
infiammatory and immune response of the stomac epithelium, that in turn 
may cause genetic alterations and an increased risk of developing gastric 
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cancer (Altieri, F., Arcari, P & Rippa E. et al. 2013). 
 
1.2  GKN1 as gastric cancer biomarker 
Biomarkers are efficient diagnostic agents for detection and even early 
detection of diseases especially malignant diseases. Biomarkers are 
diverse biochemical components such as DNA sequence, RNAs, proteins, 
and metabolites. The final goal of biomarker application is to introduce a 
sensitive and specific indicator for a certain kind of disease (Zamanian-
Azodi et al., 2015) unfortunately, there is no specific biomarker for 
gastric cancer. Previous studies aimed to disclose putative biomarkers by 
comparing the differential proteins between matched cancer and normal 
tissues. Many putative biomarkers have been identified including GRP78, 
GSTpi, Apo A1, A1AT and GKN1. Also the down-regulation of proteins 
may play an important role in carcinogenesis; Gastrokine1 (GKN1) is 
down-regulated in gastric cancer tissue compared to normal gastric tissue 
(Wu et al., 2014).The cells of the antral gastric mucosa synthesize GKN1. 
Previously known as AMP-18, CA11, FOVEOLIN, and TFIZ, was 
formally named ‘GKN1’ by the HUGO Gene Nomenclature Committee 
for its gastric specific expression and its highly conserved presence in the 
gastric mucosa of many mammalian species. (Martin et al., 2003; Oien et 
al., 3003) GKN1 belongs to a family of genes encoding stomach-specific 
proteins formed by 3 known members: GKN1, GKN2 and GKN3. The 
GKN1 gene (CA11) is located on the chromosome 2p13 and contains 6 
exons separated by relatively short introns that encode a small protein of 
about 185 amino acids containing a conserved central structural 
BRICHOS domain of about 100 amino acids including two conservative 
cysteine residues most likely involved in disulfide bridges; a COOH-
terminal segment, showing considerable divergence between the GKN 
paralogs and the Hydrophobic NH2-terminal signal peptide, that acts as a 
transmembrane anchor and/or signal peptide. 
The acronym “BRICHOS” refers to three proteins in which the domain 
was observed originally: BRI2, which is expressed in neurons and related 
to familial British and Danish dementia (FBD and FDD); 
Chondromodulin-I (ChM-I), a cartilage-specific glycoprotein related to 
chondrosarcoma and Lung Surfactant Protein C (SP-C), related to 
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respiratory distress syndrome (RDS) (Walsh-Reitz M.M et al. 2005); 
(Sánchez-Pulido et al., 2002). The BRICHOS domain shows several 
motifs of functional significance (Figure 1). 
 
 
Figure 1. GKN1 genomic location and GKN1 human transcript. (upper panel) 
Chromosome bands according to Ensembl and genomic location according to GeneLoc. 
(lower panel) GKN11 protein structural prediction. 
 
Immunoelectron microscopy indicated that GKN1 protein is localized 
within the granules just under the apical plasma membrane, suggesting 
that it is a secreted rather than an integral membrane protein acting 
primarly in the extracellular and luminal environment. The human protein 
expression is confined to the gastric epithelium, in particular in the 
surface mucous cells, except for trace levels in the uterus and placenta 
and it is richly expressed in the stomach of healthy individuals, but it is 
absent in gastric cancer tissues  (Martin et al., 2003; Oien et al., 3003)  
(Figure.2). Moreover, our research team observed that the protein is 
down-regulated in samples from H. pylori infected gastric mucosa that is 
considered as one of the leading cause for gastric cancer development. 
Early work reported that the protein is involved in the replenishment of 
the surface lumen epithelial cell layer, in maintaining mucosal integrity 
and could play a role in cell proliferation and differentiation (Lacy et al, 
1993; Podolsky et al., 1997) . After gastric mucosa injury, restoration may 
occur very rapidly in the presence of GKN1 (Rippa et al., 2007) In 
contrast, if the protein is down regulated, the repair process may be 
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obstructed. Probably the protein may exert its protective effect by 
increasing accumulation of specific tight and adherens junction proteins 
and also protecting their loss after injury (Walsh-Reitz et al., 2005; 
Sánchez-Pulido et al., 2002) (Figure 3). 
 
 
 
 
 
Figuure 2. Expression of GKN1 by Western blot analysis. Upper panel. Analysis of 
cell extracts from H.p (+) and H.p. (-) biopsies and from tumoral (t) and non-tumoral (nt) 
tissues. Lower panel. Immunohistochemistry of normal gastric tissue; B) Intestinal 
metaplasia; C) Intestinal type gastric cancer. 
 
 
Figure 3. Proposed pathways by which AMP-18 protects the mucosal barrier and 
facilitates assembly of tight junction proteins. 
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Because a disruption in gastric homeostasis may result in the 
transformation of normal epithelial cells into cancer cells and permit 
cancer cells to proliferate and invade, there is no doubt that inactivation of 
GKN1 may render the gastric mucosa vulnerable to carcinogens or gastric 
injury, and eventually trigger genetic alterations in cancer-related genes, 
including oncogenes and tumor suppressor genes. Even if the biological 
function of GKN1 is still unclear, the protein may act as a functional 
tumor suppressor in gastric epithelial homeostasis and its loss of 
expression could make possible gastric carcinogenesis. 
 
1.3 Biological activities of Gastrokine 1 
Gkn1 belongs to the BRICHOS superfamily whose members are all 
associated clinically with dementia, respiratory distress syndrome and 
cancer (Sánchez-Pulido et al., 2002). Molecular studies on the BRICHOS 
domain function have suggest that it has a range of possible roles, 
including intracellular trafficking, pro-peptide processing, chaperone 
function and secretion. The hydrophobic region and Brichos domain in 
GKN1 seem to suppress gastric cancer cell growth, reduce cell viability, 
proliferation and colony formation in AGS cells. It might be the main 
functional domain for the tumor suppressor activity (Yoon et al., 2013). 
Furthermore our group reported that GKN1 has anti-amyloidogenic 
properties thus functioning as a chaperone directed against unfolded 
segments and with the ability to recognize amyloidogenic polypeptides 
and prevent their aggregation (Altieri et al., 2014). Numerous studies 
have described frequent loss of GKN1 expression in gastric cancer (Oien 
et al., 2003), demonstrated that GKN1 mRNA was abundant only in 
normal human stomach, in all areas (cardia, body and antrum), but absent 
in gastric adenocarcinomas and gastro-esophageal adenocarcinomas cell 
line. Infact seems that the loss of expression of GKN1 may increase the 
risk of developing gastric disease. To understand the biological function 
of the protein in the normal physiology of the gastric mucosa many 
studies were carried out but no one has clarified its role. (Toback et al., 
2002), proposed that GKN1 protein could have mitogenic impacts on 
intestinal epithelial cells. In contradiction to its protective and mitogenic 
activity whereas (Shiozaki et al., 2001), found that GKN1 was capable of 
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inhibiting cell proliferation after transfection, by reducing colony 
formation in MKN-28 gastric carcinomas cells. In order to characterize 
the structural and functional properties of the protein, our group produced 
a human recombinant GKN1 (hrGKN1) (Pavone et al., 2013) and it was 
tested on normal and tumors cell through a MTT assay which showed that 
the protein reduced cells proliferation of gastric cancers cells compared to 
human embryonic kidney cells (HEK293) and non-gastric cancer cells 
(H1355). 
GKN1 can also induce apoptosis and senescence. (Xing et al., 2012; 
Rippa et al., 2011) In fact restoration of GKN1 expression resulted in cell 
cycle arrest at the G1/s or G2/M phases caused by a down regulation of 
positive cell cycle regulators, including CDK4, cyclin D1, E2F, cdc25 
and cyclin B, and an up regulation of negative cell cycle regulators, 
including p16 and p21. Furthermore our group investigated the effect of 
GKN1 on gastric cell line  (Figure 4). 
 
 
 
 
Figure 4. Effect of recombinant GKN1 on cell growth. The effect of GKN1 on cell 
growth was evaluated by the MTT assay after incubation of the cells with GKN1 at 
different times and concentrations. AGS cell growth in the absence (!) or in the 
presence of 0.5 µM (") or 3 µM (!) GKN1. H1355 cells growth in the absence (!) or 
in the presence of 0.5 µM (") or 3 µM (!) GKN1. HEK 293 cells growth in the 
absence (!) or in the presence of 5.5 µM ("), 11 µM (!)  and 18 µM (#) GKN1, 
respectively. 
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Figure 5. Effects of transfected GKN1 on cell death. Cell death was measured after 
transfection by TUNEL assay. Representative flow cytometry of cells treated with 
lipophectamine, cells transfected with empty pCDNA 3.1, cells transfected with GKN1 
before and after incubation with antibody anti-FasL. Value from five independent 
experiments with similar results. 
 
The overexpression of the protein in AGS and MKN28 cells stimulated 
higher expression of Fas receptor and sensitivity to Fas-ligand- induced 
apoptosis (Rippa et al., 2011) (Figure 5). 
Recent evidence has also demonstrated that GKN1 is involved in 
gastric mucosal inflammation by regulating production of inflammatory 
mediators, including NF-kB, COX-2 and cytokines and inhibit the 
carcinogenetic potential of H. pylori trough the direct binding to CagA at 
the extracellular level and increasing the expression of antioxidant 
enzymes at the intracellular level (Yoon et al., 2013). Subsequent study 
found that GKN1 is involved also in epithelial mesenchyme transition, a 
process observed in response to injury, organ fibrosis and cancer. In 
particular the recovery of GKN1 expression induces the conversion of 
spindle-shape cells with abundant cytoplasm to circular-shaped cells, and 
suppresses cell migration and invasiveness abrogating the expression of 
PI3K/akt pathway proteins, concomitant with the re-expression of E-
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cadherin (Yoon et al., 2013). All these data taken together show that 
GKN1 has a very important role in maintenance of gastric mucosal 
homeostasis and its early loss of function may facilitate gastric 
carcinogenesis. 
 
1.4 Scientific hypothesis and aim of the work 
On the basis of this data and in order to better understand the functional 
role of GKN1, the main target of this thesis was to explore whether 
GKN1 was a possible informative gastric cancer biomarker. 
The second part of the work aimed highlight molecular interactors of 
GKN1 and to analyze if these interactors could represent also new 
possible biomarkers for gastric cancer.  
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2. Materials and Methods  
 
2.1 Biological samples preparation  
Fecal sample. 1 g of sample was freeze and thawed at -80 ° C (x 2 times). 
Subsequently, the sample was suspended in RIPA buffer containing 0.1% 
SDS at 2: 1 ratio (w/v), hold on ice for 30 min, centrifuged at 4 ° C for 15 
'at 14,000 rpm and the resulting supernatant was used for Western 
blotting analysis.  
Gastric juice sample. Two samples of gastric juice were collected from 
two healthy subjects at Cardarelli Hospital (GJ1 and GJ2). 5 mL of GJ 
were precipitated according the acetone method above described. After 
centrifugation, samples were washed once and re-suspended in 
rehydration buffer and analyzed by Western blotting. 
Serum sample for western blot analysis. Generally, 1 ml of serum was 
diluted 1:1 with H2O and centrifuged at 4,000 rpm in Centricon 30 in 
order to separate BSA. Filtered sample was then lyophilized overnight, 
re-suspended in 50 µL H2O and analyzed by Western blotting of dot blot. 
 
2.2 Serum collection  
A total of 50 serum samples will be obtained from patients with GC and 
from healthy individuals were collected in collaboration with the Clinical 
Chemistry Lab of University of Naples Federico II and used in a frist 
approch to detected GKN1 protein levels using the ELISA assay (Cloud 
Clone Corp.). Blood samples will be collected in tubes with no 
anticoagulants and will be centrifuged at 3000 rpm for 10 min at 4 °C to 
completely remove cellular components. The collected serum will be 
stored at -80 °C. Written informed consents has been provided by all 
patients and healthy volunteers.  
 
2.3 Western blot analysis 
Samples were separated by SDS-PAGE, electrotransferred to PVDF 
membrane and reacted with the specific mouse anti-GKN1 antibody 
(detection limit: 0,1ng/mL) to analyze the levels of protein expression in 
biological samples. Immunoblots were visualized using HRP-conjugated 
secondary antibody and ECL Western blot detection kit (GE Healthcare). 
Materials and Methods 
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2.4 RNA purification and cDNA synthesis  
Serum or plasma samples will be lyzed in QIAzol Lysis Reagent 
(Qiagen). Total RNA from 1 mL of serum sample was prepared using 
miRNeasy Serum/Plasma Kit (Qiagen). RNA concentration was 
measured using the NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific). One microgram of total RNA was retro-transcribed with the 
Quantitect Reverse Transcription kit (Qiagen, Germany). 
 
2.5 Semiquantitative RT-PCR 
Four µl of cDNA were amplified with 1unit of Taq DNA Polymerase 
(Invitrogen) in the buffer provided by the manufacturer which contains no 
MgCl2.. Reactions were carried out in the PTC-0150 Mini-Cycler 
(Biorad). A first cycle of 5minutes at 95°C followed by 30 cycles (30 
seconds at 95°C, 40 seconds at 58°C, 30 seconds at 72°C) and 10 minutes 
at 72 °C. To set up the procedure, we first selected 4 different pairs of 
primers designed spread over the sequence of GKN1 cDNA. In addition, 
already well known pairs of primers for GAPDH were used as a control.  
Primers: F1-cctctgtccactgctttcgt, R1-tggttgcagcaaagccattt; 
F2-gcttcagggtaagggaccag, R2-cttgcctcttgcatctcctca;  
F3-ctttctagctcctgccctagc, R3-gttgcagcaaagccatttcc;  
F4-caacaatgctggaagtgggc, R4-tcccttaccctgaagcttcttt. 
 
2.6 Construction of the plasmid DNA standard  
Results on serum samples were evaluated by absolute quantitation using 
GKN1 cDNA cloned in the pCDNA3.1 expression vector (pCDNA3.1-
flGKN1) (Rippa et al., 2012). The content of positive recombinant 
plasmid was quantified using spectrophotometer. qRT-PCR standard 
curve was constructed using dilution from a standard plasmid solution of 
about 2.5 µg/µL. 
 
2.7 Real-time PCR  
Real-time PCR quantification will be performed using a CFX 96 
thermocycler (Bio-Rad) with SYBR green PCR Master Mix (Bio-Rad) to 
detect the presence of GKN1 in serum samples. The following 
primers for GKN1 cDNA sequence will be used: 
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Fw gcttcagggtaagggaccag, Rev cttgcctcttgcatctcctca.  
 
2.8 Elisa kit Cloud-Clone Corp for detection of GKN1 
For detection of GKN1 levels in serum it’s been used a specific ELISA 
kit, the kit is a sandwich enzyme immunoassay for in vitro quantitative 
measurement of GKN1 in human serum, plasma, tissue homogenates and 
other biological fluids. The assay is conducted according to the protocol. 
Briefly: the microliter plate provided in this kit has been pre-coated with 
an antibody specific to GKN1. Standards or samples are then added to the 
appropriate microliter plate wells with a biotin-conjugated antibody 
specific to GKN1 (detection limit 0,057 ng/mL). Next, Avidin conjugated 
to Horseradish Peroxidase (HRP) is added to each microplate well and 
incubated. After TMB substrate solution is added, only those wells that 
contain GKN1biotin-conjugated antibody and enzyme-conjugated Avidin 
will exhibit a change in color. The enzyme-substrate reaction is 
terminated by the addition of sulphuric acid solution and the color change 
is mesaured spectrophotometrically at a waveleangth of 450nm ± 10 nm. 
The concentration of GKN1 in the samples is then determined by 
comparing the O.D. of the samples to the standard curve. ELISA kit for 
GKN1 detection was calibrated using as standard the recombinant protein 
(rhGKN1) that allowed to determine a concentration range of GKN1 of 
0.5 - 10 ng/ml of serum (Fig.3). The assay was subsequently performed 
on about 30 fresh sera from healthy subjects in different analysis 
conditions: any serum samples are treated at 56 °C for 20 minuts to 
remove the high PM proteins, others are analyzed whitout preliminary 
treatment. 
 
2.9 AMP18biotinylation, affinity pull-down and mass spectrometry 
analysis  
The biotinylation of recombinant AMP18 (rAMP18) (Pavone et 
al.2013) was performed by incubating 1.4 mg of protein with 20 
mM NHS-biotin (N-hydroxysuccinimide biotin) (Thermo 
Scientific) for 30 min at room temperature. To eliminate the excess 
of biotin, the sample  was then subjected to gel filtration 
chromatography on a Sephadex G-25 column. The biotinylated 
rAMP18 was quantified with the Bradford method. Biotinylated 
Materials and Methods 
12 
 
rAMP18 (650 µg) was then incu- bated with 9 mg of Streptavidin 
MagneSphere Paramagnetic par- ticles/beads (Promega, Madison, 
USA) for 1 h at room temperature under stirring in order to 
promote the bond between the bio- tinylated rAMP18 and 
streptavidin. The same volume of buffer without protein was 
loaded as negative control. Magnetic beads were washed 3 times 
with 1 PBS according to manufacturer's instructions. The rAMP18-
bounded beads were then incubated overnight at 4°C with 1.8 mg 
of protein extract from human non- tumoral gastric mucosa. 
Following beads washing with 1 PBS, elution was performed with 
2 mM D-biotin; the eluted samples were freeze-dried and stored at 
20 until mass spectrometry analysis.  
Proteins from pooled fractions were precipitated with trichloro acetic 
acid (TCA) and dissolved in 100 µL of 50 mM ammonium bicarbonate. 
Disulphide reduction was performed with 2.5 mM DTT at 55 °C for 15 
min, followed by carbamidomethylation with 7.5 mM iodoacetamide at 
room temperature in the dark for 15 min. Protein digestions were 
performed at 37 °C for 3 h by adding 5 µL of a 70 ng/ mL Tosylamido-2-
Phenylethyl Chloromethyl Ketone (TPCK) porcine trypsin solution. Mass 
spectrometry analysis was performed using a quadrupole time of flight 
(ESI-Q-q-TOF) mass spectrometer equipped with an electrospray 
ionization source. Tryptic peptides were separated by means of a modular 
CapLC system (Waters, Manchester, UK) as reported elsewhere 
(A.Chambery et al. 2009). Samples were loaded onto a C-18 precolumn 
(5 mm length x 300 mm ID) at a flow rate of 20 mL/min and desalted for 
5 min with a solution of 0.1% formic acid. Peptides were then directed 
onto a symmetry-C18 analytical column (10 cm 300 mm ID) using 5% 
CH3CN, containing 0.1% formic acid at a flow rate of 5 mL/min. The 
elution was obtained by increasing the CH3CN/0.1% formic acid 
concentration from 5% to 55% over 60 min. The precursor ion masses 
and associated fragment ion spectra of the tryptic peptides were mass 
measured with the mass spectrometer directly coupled to the 
chromatographic sys- tem. Electrospray mass spectra and tandem MS/MS 
data were ac- quired on the Q-TOF mass spectrometer operating in the 
positive ion mode with a source temperature of 80 °C and with a potential 
of 3500 V applied to the capillary probe. MS/MS data on tryptic peptides 
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were acquired in the data directed analysis (DDA) MS/MS mode. A 
maximum of three precursor masses was defined for concurrent MS/MS 
acquisition from a single MS survey scan. MS/ MS fragmentation spectra 
were collected from m/z 50 to m/z 1600. The MS/MS data were 
centroided, deisotoped, and charge- state- reduced to produce a single, 
accurately measured monoisotopic mass for each peptide and the 
associated fragment ions. For protein identifications, processed spectra 
were searched against Swiss-Prot database (release 2012_06; 20238 
entries) using the Mascot soft- ware (version 2.2 from Matrix Science) 
applying the Homo sapiens taxonomy restriction. Fixed (Cys as S- 
carbamidomethyl derivate) and variable (Met as oxidized methionine) 
modifications were considered, allowing one trypsin missed cleavage site 
and a mass tolerance of 100 ppm. Identifications were accepted as 
positive when probability scores were significant at p < 0.05. To increase 
the SLC26A3 coverage identification was also performed by using the 
Protein Lynx Global Server 2.3 software (Waters) to search monoisotopic 
masses against an in house- developed database of SLC26A3 sequence. 
 
2.10 Cell culture, transfection and western blotting  
Human gastric adenocarcinoma cell line (AGS) was grown in DMEM-
F12 (Dulbecco's modified Eagle medium-Cambrex) sup- plemented with 
heat inactivated FBS, 100 U/ml penicillin, 100 mg/ mL streptomycin, 1% 
L-glutamine at 37 °C in a 5% CO2 atmosphere and transfected with 4 mg 
of empty vector pcDNA 3.1 or pcDNA3.1- flAMP18. The efficiency of 
transfection of gastric cancer cells with flAMP18 was always evaluated 
by a parallel transfection using EGFP vector as control. In general, after 
transfection, the average value of the ratio between number of green 
fluorescent cells/total number of cells was 0.5 ± 0.1. Proteins from cell 
extracts were analyzed by Western blotting using mouse anti-SLC26A3 
antibody at a dilution of 1:1000 and mouse anti-AMP18 at 1:500. 
Detection was per- formed using the enhanced chemiluminescence 
detection kit (SuperSignal West Pico) following manufacturer's 
instructions. All films were analyzed by using the Image J software.  
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2.11 Ni-NTA agarose pull-down  
Transfected AGS cell extracts (500 mg) were incubated with 50 mL of 
Ni-NTA Agarose (Qiagen) pre-equilibrated with binding buffer (50 mM 
NaH2PO4, 300 mM NaCl pH 8.0) for 16 h at 4 C°. After incubation, the 
resin was washed 4 times with binding buffer containing 10 mM 
imidazole to reduce aspecific protein binding, resuspended in 30 mL of 
SDS loading buffer, heated to 95 C°for 5 min and subjected to Western 
blot analysis. 
 
2.12 RNA isolation and RT- PCR  
RNA was extracted with the TRIZol reagent (Invitrogen, UK). Total 
RNA amount was quantified by using a Nanodrop 1000 
spectrophotometer (Thermo Fisher Scientific, UK). One microgram of 
total RNA was retro-transcribed with the Quantitect Reverse 
Transcription kit (Qiagen, Germany) and cDNA was diluted for semi-
quantitative real-time PCR analyses on LightCycler 480 Real-Time PCR 
System (Roche, Germany) with Taqman probe chemis- try. Additional 
information are reported in Supplementary data. Results were normalized 
on the housekeeping glyceraldheyde-3-phosphate dehydrogenase 
(GAPDH) gene. A comparison of SLC26A3 expression levels was 
performed before and after the transfection with the pcDNA3.1-flAMP18 
as previously described (E.Rippa et al. 2011) and in non-tumoral (N) 
versus tumoral (T) tissues. Relative gene expression was calculated 
according to (Pfaffl et al., 2011) by using the DDCt method (where DDCt 
corresponds to the increase in the threshold cycle of the target gene with 
respect to the increase in the threshold cycle of the housekeeping gene, 
GAPDH). Hence, the final quantification value for each condition 
indicated the relative change of gene expression of the target gene in non-
tumoral (N) tissues (or non-transfected AGS cells) compared to the paired 
control tumoral (T) stomachs from the same patients (or from the same 
AGS cells transfected with pcDNA3.1-flAMP18). SLC26A3 mRNA 
integrity of was verified by RT PCR on total RNA prepared from 
transfected and non-transfected AGS cells. The following primers were 
used: forward tggcagctagtgtggcattt, reverse ctttgttgcgcttgcgtaga, 
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corresponding to the amino acid regions A489-F494 and L568-K573 of 
SLC26A3, respectively. The amplified PCR product length was 258 bp. 
 
2.13 Population  
The study population comprised 27 patients with GC recruited at Hospital 
A. Cardarelli, Naples, Italy. All patients were interviewed 
regarding smoking habit, alcohol intake and chronic use of drugs. 
Pathologist G. de Dominicis performed the macro dissection of tumor and 
non-tumor tissues of GC patients during surgery. Gastric cancer was 
classified according to Lauren criteria. The study reported in the 
manuscript has been carried out in the frame of a research protocol 
entitled “Role of gastrokine 1 in gastric cancer” that has the approval 
from the Ethic Committee of the University of Naples Federico II 
(Comitato Etico Universita Federico II). The assigned protocol number of 
the study was 34/15. 
 
2.14 Immunohistochemistry  
Four-micrometer thick, formalin-fixed, paraffin-embedded tis- sue 
sections were stained with hema- toxylineeosin for light microscopic 
examination. Consecutive sections were stained for 
immunohistochemistry using polyclonal rabbit (Sigma) anti- SLC26A3 
antiserum (dilution 1:500). 
 
2.15 Statistical analyses  
Statistical analyses were performed by two-tailed paired Stu- dent's t-test 
using KaleidaGraph 4.1.1 software. Data were reported as means ± 
standard deviation (SD). The significance was accepted at the level of p < 
0.05.  
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3. Results 
 
Part A. Evaluation of the expression of gastrokine 1 in body fluids 
To assess if GKN1 could represent a possible biomarker for gastric 
cancer, the first approach was to ascertain its presence in most important 
human biological fluids taken from healthy subject. This approach was 
necessary before to follow its presence in samples from patients with 
gastric cancer. Therefore, we analyzed the following human fluids: fecale, 
gastric juice and blood serum. 
 
3.1Body fluid analyses: Western blotting on  fecal and gastric juice. 
We first analyzed easy withdrawal samples such as fecal. Subsequently, 
we tested fecal sample. Protein extract on freeze samples were analyzed 
by western blotting using mouse anti-GKN1 antibody. (Figure 6) shows 
the result of this analysis using as control the protein extract from human 
gastric mucosa. 
Moreover, we have avaluated GKN1 espression levels in gastric juice 
of two healthy subjects: the samples were precipitated according the 
aceton method as described in Materials and Methods and analyzed by 
western blotting using mouse anti-GKN1 antibody. (Figure 7) show the 
result of the protein expression using as a control the protein extract from 
human gastric mucosa. 
 
Figure 6. Analysis of GKN1 expression in human faecal.  Samples from normal 
individual were collected and analyzed by Western blots using mouse anti-GKN1 
antibody. Lanes: 1, h.fecale 1 (45 ug, 32 µL); 2, human gastric mucosa (30 µg); 3, 
h.fecale 2 (45 ug, 32 µL); 4, h.fecale 3 (45 ug, 32 µL); 5, h.fecale 4 (45 ug, 32 µL); SM, 
size marker; 6, human gastric mucosa (30 µg). 
Results 
17 
 
Using western blotting to detect the presence of GKN1 in urine, fecal and 
gstric juice semples, unfortunalely, we did not found the protein in the 
examined samples. 
 
 
 
 
Figure 7. Analysis of GKN1 expression in human gastric juices.   Lanes: 1 and 2, 
gastric juice sample 1 and 2 (32 µL), respectively; 3, gastric juice sample 2 after wash 
(32 µL); 4, human gastric mucosa (30 µg). 
 
3.2 Body fluid analyses: Western blotting on Human serum 
Because human serum is a rich source of biochemical products that can 
act as indicators of the physiological or clinical status of a patient, we 
subsequently exploited the potentiality of GKN1 as gastric cancer 
biomarker in this biological fluid. We first tried to use Western blotting 
technique to analyze human sera of healthy individuals. Because of the 
unusually high abundance of human serum albumin (HSA) in serum that 
can interfere with the resolution and sensitivity of several proteome 
techniques, samples were partially purified by Centricon 30 to remove 
high molecular weight proteins and then analyzed by Western blotting 
comparing the intensity of the signals with that of human gastric mucosal 
extract. 
As show (Figure 8-A) show the result of the protein expression on 
intact serum of healthy and pathological samples instead, (Figure 8-B) 
show the result of protein expression on serum after protein concentration 
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using as a positive control the protein extract from human gastric mucosa 
and as negative control BSA to be sure of have removed the proteins that 
could have been interfere with analysis. Also in this case, detection with 
monoclonal mouse anti-GKN1 antibody did not show any positive signals 
compared to that shown by human gastric mucosal extract. 
This assess if the results obtained by Western blotting would have 
been comparable with that of another methods, serum samples from 
healthy subject were also analyzed with ELISA kit for GKN1. As 
reported in (Figure 9), the calibration curve obtained using as control 
sample recombinant GKN1 showed a lower detection limit for the ELISA 
method of about 0.1 ng/mL. Nevertheless, the analyses performed on 
human sera of healthy individuals did not give any positive 
spectrophotometric answer at 450 nm. 
 
 
Fig. 8. Analysis of GKN1 expression in human sera. A.  Lanes: 1, 2 and 3, intact 
serum samples (32 µL) from normal subjects; 4 and 5, intact serum samples from 
subjects with GC (32 µL); 6, human gastric mucosa (30 µg); SM, size marker; 8 and 9, 
intact serum samples  (32 µL) from normal subjects. B. Samples of human serum from 
healthy subjects, after concentration in Centricon 30, were analyzed by dot blot using 
mouse anti-GKN1 antibody. Lanes 1, 2, 3 and 4: 1, 2, 5 and 10 µL, respectively of 
concentrared serum sample 1120 and 1140; 1, 2, 5 and 10 µg, respectively of gastric 
mucosa and BSA. 
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Figure 9. Analysis of GKN1 expression in human sera by ELISA method. GKN1 
ELISA detection standard curve constructed according the kit instructions protocol. 
GKN1 recombinant protein standard (▲); curve fit (-). 
 
3.3 Body fluid analyses: qRT-PCR on Human serum 
Subsequently, it was tried to detect GKN1 mRNA in sera of healthy 
volunteers. Four sets of PCR primers, spanning over GKN1 coding 
sequence, were defined by using PrimerBlast Server (Figure. 10) and used 
to perform semi-quantitative PCR on fresh human sera. As reported in 
(Figure. 11) (lanes a), all primer couples were able to amplify the 
corresponding GKN1 cDNA region giving PCR products of the expected 
length. This finding suggested the presence of a full GKN1 mRNA in the 
samples analyzed. To check if the four PCR products were corresponding 
to GKN1 cDNA, PCR sequencing analyses were performed. The results 
confirmed that the nucleotide sequences of the four PCR products were 
encoding GKN1 (not shown). Therefore, we decided to use the qRT-PCR 
strategy to detect GKN1 mRNA in the serum obtained from a population 
of wealthy subject and in that from patients with diagnosis of gastric 
cancer. We took advantage from a collection of sera withdrawn from 
patients with a diagnosis of gastric cancer that underwent surgical 
treatment. The clinicopathologic characteristics of the gastric cancer 
patients are outlined in Table 1. The intestinal type was well 
differentiated in one, moderately differentiated in three and poorly 
differentiated in the remaining cases, while as far as concerns stage, these 
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were all advanced. Diffuse type GC was poorly differentiated and 
advanced in all cases. The non-tumoral areas of intestinal type GC 
showed a variable degree of gastric atrophy with diffuse IM, instead, the 
peritumoral areas of diffuse type GC showed a variable degree of non 
dysplastic inflammation. Characterization of non-tumoral gastric mucosa 
(N) from tumoral one was based on the macroscopic aspect of the normal 
tissue compared to the tumoral one, as evaluated from the hospital 
pathologist, and from the analysis by Western blotting of GKN1 
expression level in non-tumoral and tumoral tissues of each patient (data 
not shown) (Di Stadio et al., 2015). qRT-PCR was performed by absolute 
quantification by a standard curve method constructed using as reference 
DNA a plasmid containing flGKN1 cDNA (Rippa et al., 2011). We used 
serial 10-fold dilutions of plasmids to construct a standard curve by 
plotting the logarithm of the plasmid copy number against the measured 
cycle values. The standard curve had a wide range of DNA copies/µl 
(from 3.78x101 up 3.78x108) with a linear correlation (R2) of 0.99351, 
and a slope of -3.909 (Figure. 12-A). The level of circulating GKN1 
mRNA of all 23 healthy samples showed a median cycle number value of 
29.6673 (range 27.702–31.380). GC patients gave a median Ct value of 
30.1269 (range 28.713–31.279). The statistical evaluation of the results 
using Student t-Test of unpaired data with unequal variance, indicated a 
non-significant difference among the two groups (p = 0.1138) (Fig.12-B). 
From the standard curve, the mean circulating copies of GKN1 mRNA 
were 1.81x105 and 2.38x105 copies/ml in patients and healthy individuals, 
respectively. 
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Figure 10. PCR primers for GKN1 mRNA detection in Human sera. Nucleotide 
sequence of GKN1 cDNA. The coding region is represented in capital letters, start and 
stop codons are underlined. PCR primers pairs F1-R1, F2-R2, F3-R3 and F4-R4 are 
highlighted in gray, respectively. 
 
 
Figure 11. Evaluation of the expression of GKN1 mRNA in human sera. 
Representative semi-quantitative PCR performed on a serum of a healthy subject 
performed before (lanes a) and after (lanes b) storage of the sample at 4°C for 24 h. PCR 
reactions were carried out using the primers pairs F1-R1, F2-R2, F3-R3 and F4-R4 as 
indicated in Figure 10.   
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Figure 12 A. standard curve had a wide range of DNA copies/µl (from 3.78x101 up 
3.78x108) with a linear correlation (R2) of 0.99351, and a slope of -3.909 B. statistical 
evaluation of the results using Student t-Test. 
 
Part B. Search for other possible biomarker for gastric cancer 
 
3.1 Identification of SLC26A3 as an interaction partner of rAMP18 
Functional proteomic strategy was subsequently exploited with the 
purpose to identify other possible markers for gastric cancer. Tacking 
advantage from the availability of recombinant GKN1 (rGKN1), a 
functional proteomic strategy was setteled. Biotynilated GKN1 bound to 
streptavidin beads, was incubated in the presence of non-tumoral gastric 
mucosal cell extract as described in the Methods section. After 
appropriate washing, beads were eluted with 2 mM D-biotin and the 
resulting fractions were pooled and analyzed by mass spectrometry. Only 
in the sample treated with rGKN1, besides the presence of AMP18, it was 
interestingly identified the membrane channel protein SLC26A3, also 
known as Down-Regulated in Adenoma (DRA). Such protein belongs to 
the family of solute-linked carrier (SLC26) that code for proteins capable 
of carrying a variety of monovalent and divalent anions. 
 
3.2. Validation of the interaction by pull-down and western blot analyses 
The interaction between GKN1 and SLC26A3 was first confirmed by 
applying a traditional pull-down strategy. Taking advantage of the (His)6-
tag sequence in the pCDNA3.1-flAMP18 vector (Rippa E. et al. 2007) , a 
pull-down was performed following transfection of the AGS cells with 
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the pCDNA3.1-flAMP18 construct encoding for the full length AMP18 
protein (Rippa E. et al. 2007).As reported in (Figure 13), in cells 
transfected with flAMP18, SLC26A3 was specifically pulled-down 
toghether with flAMP18 as detected by anti-SLC26A3 mouse antibody, 
thus confirming its interaction with AMP18. In this experimental setting, 
a band with a molecular weight of about 32 kDa was detected for 
SLC26A3. The specificity of the interaction was verified by the absence 
of similar bands in the negative control samples transfected with 
pcDNA3.1 empty vector (Figure 13, lane 2) and in the absence of cell 
extract (Figure 13, lane 3). 
 
 
Fig.13 Pull-down experiment. AGS cells extracts after 24 h after transfection with 
pcDNA3.1-flAMP18 were pulled-down with Ni-NTA agarose and washed with 10 mM 
imidazole. The Ni-NTA resin was directly loaded on SDS-PAGE and analyzed by 
western blot by using mouse anti-SLC26A3 (A) and mouse anti-AMP18 antibody (Ab) 
(B). (Lane 1) AGS cells transfected with pCDNA3.1-flAMP18 encoding for full length 
AMP18 (flAMP18); (lane 2) AGS cells transfected with pCDNA3.1 as negative control; 
(lane 3) Ni-NTA alone; (lane 4) control AMP18 expression in AGS cells transfected 
with pCDNA3.1-flAMP18 encoding flAMP18.  
3.3 Expression of SLC26A3 in gastric tissues and gastric cancer cells 
On the bases of results obtained, we analyzed the expression profile of 
SLC26A3 in gastric tissues and in gastric adenocarcinoma cell lines. As 
reported in Figure. (14 A), a protein of about 86 kDa was detected in 
gastric tumoral (T) and non-tumoral (N) tissues whereas, as found in the 
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pull-down experiment (Fig. 13A), a band of about 32 kDa was mainly 
detected within the AGS adenocarcinoma cells, together with a weaker 
band of 86 kDa. To better investigate the expression of SLC26A3 in the 
AGS gastric cancer cell line, both cell lysates and comparable amounts of 
whole membrane pellets of control and flAMP18 transfected AGS cells 
re-suspended in 5x Laemmli buffer were analyzed by western blotting. As 
reported in Fig. 14B, the presence of the 32 kDa band was detected in 
AGS cell lysates whereas, in the whole membrane pellet, the 86 kDa band 
was also present with a lower intensity with respect to the 32 kDa band. 
The 86 kDa protein was also found to be highly expressed in non-tumoral 
gastric antrum mucosa (Fig. 14B). 
 
3.4 Evaluation of SLC26A3 expression levels in gastric cancer tissues 
Taking advantage from our collection of surgical specimens, we then 
analyzed the expression level of SLC26A3 in human non-tumoral and 
tumoral gastric tissues. Samples were obtained from patients with a 
diagnosis of gastric cancer that underwent surgical treatment. 27 paired 
samples of gastric tissues from same subjects were dissected after 
intervention in non-tumoral (N) and tumoral (T) area. The 
clinicopathologic characteristics of the gastric cancer patients are outlined 
in Table 1. The intestinal type was well differentiated in one, moderately 
differentiated in four and poorly differentiated in the remaining 
twentytwo cases, while as far as concerns stage, these were all advanced. 
Diffuse type GC was poorly differentiated and advanced in all cases. The 
non-tumoral areas of intestinal type GC showed a variable degree of 
gastric atrophy with diffuse IM, instead, the peritumoral areas of diffuse 
type GC showed a variable degree of non dysplastic inflammation. 
Characterization of non-tumoral gastric mucosa (N) was based on the 
macroscopic aspect of the normal tissue 
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Fig.14 Expression of SLC26A3 in gastric tissues and gastric cancer cells. A. 
Expression of SLC26A3 in human gastric tissues and AGS cell line using mouse 
anti- SLC26A3 antibody. Lanes: T, tumoral tissue (20 mg); N, non-tumoral 
tissue (20 mg); 1e3, AGS cell extracts 10, 20 and 30 mg, respectively. B. 
Expression of SLC26A3 in non- transfected and transfected AGS cell line with 
pcDNA3.1-flAMP18. Lanes: 1 and 2, cell lysate (20 mg) and whole membrane 
pellet, respectively of control AGS cells; 3 and 4, cell lysate (20 mg) and whole 
membrane pellet of transfected AGS cells, respectively; 5, gastric antrum 
mucosal extract (20 mg). 
 
compared to the tumoral one, evaluated from the hospital pathologist, and from 
our previous work showing that AMP18 was highly expressed in gastric non-
tumoral tissues but down-regulated or totally absent both at transcription and 
translation level in GC tissues (Nardone G. et al2008) . Therefore, we first 
analyzed all the collected tissues for AMP18 expression levels. Fig. 15Aa shows 
the expression profiles of AMP18 in representative paired non-tumoral (N) and 
tumoral (T) tissues as evaluated by Western blot analysis on cellular extracts 
using mouse anti-AMP18 antibody. In all tumoral samples analyzed, it was 
observed almost total absence of AMP18. Subsequently, the same samples were 
analyzed by Western blot for SLC26A3 expression levels using mouse anti-
SLC26A3 antibody. As reported in Fig. 15Ab, in almost all paired non-tumoral 
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and tumoral samples analyzed it was observed a reduction of the band intensity 
of the tumoral sample compared to its paired tumoral one. Statistical evaluation 
of the expression levels of SLC26A3 in all paired non-tumoral (N) and tumoral 
(T) samples, evaluated from SLC26A3 bands densitometry and normalized to 
the corresponding GAPDH level (Fig. 15Ac), showed an average reduced 
expression level of SLC26A3 in tumoral areas of about 36% (Fig. 15B).  
To assess whether the SLC26A3 down-regulation occurred also at mRNA 
level, real-time PCR analyses were performed on total RNA extracted from three 
paired non-tumoral and tumoral gastric tissues in which SLC26A3 was down-
regulated at protein level. As reported in Fig. 16C, compared to non-tumoral 
tissues, the statistical evaluation of qRT-PCR results showed a similar decrease 
of SLC26A3 mRNA levels in tumoral tissues. GAPDH was used as control for 
qRT-PCR. 
 
Table 1 Clinical and histopathological characteristics of gastric cancer patients 
 
Variable n. 27 
Age at surgery (yrs) 
Mean ±  SD 
 
64 ± 13 
Range 32 - 81 
Sex M/F 16/11 
Tumor type  
Intestinal 16 
Diffuse 11 
Stomach region  
Antrum 10 
Corpus 9 
Fundus 5 
Not defined 3 
Grade of differentiation  
Well 1 (3.7%) 
Moderate 4 (14.8%) 
Poor 22 (81.4%) 
Stage  
Early 0 (0%) 
Advanced 27 (100%) 
 
Immunohistochemical evaluation of SLC26A3 (Fig 12) showed strong 
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immunostaining for SLC26A3 protein in the cytoplasm of cells from the 
superficial epithelium to the upper third of the glandular epithelium of 
colonic and gastric mucosa (Fig. 16A and 16B, respectively). The 
SLC26A3 immunopositivity was instead lower in intestinal metaplasia 
(Fig. 16C) and more reduced in the tumoral areas of GC, both in the 
superficial and glandular epithelium (Fig. 16D). Higher magnification of 
non-tumoral gastric tissue is reported in Fig. 17. 
 
 
Fig.15 Expression levels of SLC26A3 in human gastric tissues. A. Representative 
Western blot of equal amounts of cell extracts (20 mg) analyzed in 27 paired non-
tumoral (N) and tumoral (T) human gastric samples using mouse anti-AMP18 (a), mouse 
anti-SLC26A3 (b) and rabbit antieGAPDH (c) antibodies (Ab). B. Densitometric 
analysis. Statistical eval- uation of the expression levels of SLC26A3 protein in all non-
tumoral (N) and tumoral (T) paired samples was calculated from the densitometry of 
SLC26A3 bands normalized towards the corresponding densitometry of GAPDH bands. 
C. qRT-PCR analysis. Total RNA was prepared from gastric tissues and analyzed by 
qRT-PCR for SLC26A3 mRNA level compared to GAPDH mRNA as reference sample. 
Samples: N and T, non-tumoral and tumoral gastric tissues, respectively. Data from three 
experiments are reported as mean values ± SD.  
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Fig. 16. Immunohistochemical evaluation of SLC26A3 expression. A. Non-tumoral 
colonic mucosa (positive control) (IHC 20 ). B. Non-tumoral gastric mucosa. The 
submucosa shows no positivity (IHC 20 ). C. Intestinal metaplasia. D. Tumor gastric 
mucosa (IHC 20 x) 
 
Figure 17. SLC26A3 immunostaining of non-tumoral gastric cell. Cross-section of 
non-tumoral gastric glands showing the presence of parietal cells and principal cells and 
typical tubular architecture of the gastric pits. (*) Luminal part of the gastric gland. (**) 
Basolateral part of the gastric gland. Arrow indicates the basal membrane. L is the 
lamina propria (connective tissue).  
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Discussion 
Cancer is the third foremost cause of death worldwide; there is no proper 
early detection and treatment methods available relative to various 
cancers. Gastrointestinal cancers are among the most rampant 
malignancies and are fatal if remained uncured. Common treatments are 
chemotherapy, radiotherapy, and surgery. For this reason, the possibility 
to dispose of a biomarker for the early detection of the disease is of 
relevant importance. In fact, biomarker tests started to demonstrate their 
novel features in the detection and management of patients with different 
malignancies. Sensitivity and specificity in determining biomarkers are 
crucial due to clinical cancer detection, surveillance after treatment and 
therapy selection. A protein marker could be useful in distinguishing 
malignant from benign, differentiate from other diseases, and identifying 
each stages with high specificity and sensitivity. Biomarkers are efficient 
diagnostic agents for detection and even early detection of diseases, are 
diverse biochemical components such as DNA sequence, RNAs, proteins 
and metabolites; the final goal of biomarker application is to introduce a 
sensitive and specific indicator for certain kind of disease. Unfortunately, 
there is no specific biomarker for many kinds of malignant disease as 
Gastric cancer. Under this regards, it was a challenge to search for 
possible informative biomarkers. Being commercially available a 
sensitive anti-GKN1 antibody, several biological fluids like urine, fecal, 
gastric juice and serum were first analyze using Western blotting a in the 
latter case, also specific ELISA Kit for quantitative measurement of 
GKN1 in serum samples. No GKN1 was possible detect in the analyzed 
samples. In particular, for ELISA assay, about 30 fresh sera from normal 
subject were analyzed. Because the given detection limit of both GKN1 
antibody and Elisa kit is about 0.15 ng/mL (using as control recombinant 
GST tagged GKN1), the lack of detection of GKN1 in human sera, unless 
totally absent, might depend by a far lower concentration of the protein. 
Therefore, more sensitive detection methods for the protein in the serum 
(actually not yet available) must be used in order to ascertain this 
possibility. 
The above results prompted us to search for GKN1 at transcription 
level. It is well known that mRNA in body fluid such as blood, has been 
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proved as a novel resource to replace conventional tools for disease 
identification (Juusola J and Ballantyne J, 2003; Li et al., 2006; Miura et 
al., 2008), and successfully used as cancer-related biomarker (Anker et 
al., 1999; Rieger-Christ et al., 2003; Wong et al., 2003). In fact, mRNA 
markers have been the targets for identifying patients with colorectal, 
breast, lung, and thyroid cancers, and malignant melanoma (Kopreski et 
al., 2001; Bunn PJ Jr, 2003; Wong et al., 2004; Fugazzola et al., 2002; 
Kopreski et al., 1999). All these published studies were performed for 
testing a single mRNA marker. In this scheme, we tried to assess if GKN1 
circulating mRNA in serum might represent a biomarker for gastric 
cancer detection. The expectation was that in the sera of patients with GC, 
a lower or undetectable level of GKN1 mRNA should have been 
observed. Despite the strong down-regulation of GKN1 protein levels in 
gastric cancer, the quite comparable levels of GKN1 mRNA strongly 
indicated that this down-regulation is not observed at transcription levels 
thus suggesting translation regulation mechanism for GKN1 expression. 
The result obtained suggested to direct the search towards other non-
invasive gastric cancer biomarker such as long noncoding RNAs 
(lncRNAs), a recently discovered class of non-coding RNAs (ncRNA) 
that are emerging as a promising new class of biomarkers for tumour 
diagnosis (Xu et al., 2014). 
By using an affinity pull-down strategy, we then observed in human 
non-tumoral gastric mucosa the interaction between GKN1 and 
SLC26A3, a protein expressed in the apical membrane of intestinal 
epithelial cells, that is supposed to play a critical role in Cl- absorption and 
fluid homeostasis together with Na+/H+ exchange mediated by Na+/H+ 
exchanger 3 (H. Hayashi et al. 2002, N.C. Zachos et al. 2005).SLC26A3 
has also been shown to function as a Cl-/HCO3- exchanger in heterologous 
expression systems (M.N. Chernova et al. 2003, H. Hayashi et al. 2001, 
 J.E. Melvin et al.1999) and deletion of SLC26A3 by gene targeting 
produces chloride-losing diarrhea (CLD) in mice, a phenotype similar to 
CLD (congenital chloride diarrhea first called CCD) in humans (S. 
Wedenoja et al. 2011). The pull-down strategy used in our study was 
based on GKN1 biotinylation and MS analysis of affinity-purified 
proteins on streptavidin magnetic beads. The observed interaction was 
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confirmed by pull-down experiments using flGKN1 bound to Ni-NTA 
resin from AGS cell extracts transfected with flAMP18. In this instance, 
an intense immunoreactive band of about 32 kDa was detected with 
mouse anti-SLC26A3 antibody. Interestingly, the occurrence of a major 
SLC26A3 immunoreactive band of 86 kDa was instead evidenced in 
tumoral and non-tumoral tissues, whereas in the gastric cancer cell line 
AGS both bands were detected, although the 32 kDa band was found to 
be much more intense. The 86 kDa band corresponded to the full length 
protein as predicted on the basis of the theoretical molecular mass 
deduced from the amino acid sequence of SLC26A3 (84.5 kDa) (C.W. 
Schweinfest et al.1993, M.K. Byeon et al.1996). 
The membrane topology model of SLC26A3 (S. Makela et al. 2002, 
R.H. Moseley et al. 1999) predicts the existence of a NH2-terminal 
domain of about 500 amino acids containing 12 transmembrane segments 
(A. Bairoch et al. 2005) and an intracellular COOH-terminal region of 
250 amino acids containing two protein-protein interaction domains: a 
STAS (sulfate transporters and anti-sigma factors) domain and a PDZ-
interacting domain probably playing a regulatory role (M.R. Dorwart et 
al. 2008, S.B. Ko, W. Zeng et al. 2004, G. Lamprecht  et al. 2002, G. 
Lamprecht  et al 2004, S. Lissner et al. 2010, S. Lissner et al. 2010, H. 
Rossman et al.2005). Experimental evidence supports the hypothesis that 
the N- and C-terminal regions are located in the cytosol (M.R. Dorwart et 
al. 2008). It has been proposed that N-glycosylation protects SLC26A3 
from proteolytic enzymes in the intestine under physiological conditions, 
while deglycosylation of SLC26A3 may contribute to the pathogenesis of 
diarrhea associated with CCD. Trypsin cleavage sites of SLC26A3 are 
located in extracellular loops of the trans-membrane domain. These sites 
might be protected from trypsin digestion when HASLC26A3 is 
glycosylated (H. Hayashi et al.2012, M.K. Byeon et al. 1998). Therefore, 
the 32 kDa band observed. Therefore, the 32 kDa band observed by 
Western blotting in AGS cells might result from proteolytic processing of 
SLC26A3. This band might correspond to the C-terminal region of 
SLC26A3 probably cleaved at the level of Arg or Lys present in the last 
extra-cellular loop of the 12 trans-membrane domain model.  
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It is known that SLC26A3 is expressed in colon tissue and its down-
regulation correlates with colon tumor progression (T.M. Antalis et 
al.1998). In contrast, SLC26A3 expression in gastric tissue was not 
reported. One of the first publications in this field from Byeon et al. 
(M.K. Byeon et al.1996), described that there was no expression of DRA 
in stomach. Wang et al., 2002, further showed mild expression levels of 
DRA in the small intestine but emphasized its major role as Cl-/HCO3- 
exchanger in the colon (Z. Wang  et al. 2002). Rat DRA-specific mRNA 
expression was detected only in specific segments of the digestive tract 
(duodenum, ileum, cecum, proximal colon and distal colon) but not in the 
stomach (C. Barmeyeret al.,2007). It must be noted however, that 
SLC26A3 protein expression was detected in the fundic glands region and 
the pyloric glands region of the stomach in mice (H. Xu, J. Li et al.2001). 
In addition, the function of SLC26A3 in human gastric tissue was 
reported by Seidler and Sjoblom, 2012(U. Seidler et al.), and linked to 
HCO3- secretion that originated from the surface cells, since a similar type 
of secretion was also observed in antral mucosal. Moreover, they also 
reported that although the expression levels of HCO3- in murine stomach 
has been evaluated in about 50% and 10% of that of the duodenum and 
distal colon, respectively, these levels should be still sufficient to explain 
luminal Cl--dependent HCO3- secretory rate important for mucosal 
defence against very low luminal pH (U. Seidler et al., 2012 ). In this 
work, we showed for the first time that SLC26A3 was expressed in 
human gastric tissue and was also down-regulated in human gastric 
cancer tissues. In fact, compared to non-tumoral area, the evaluation of 
SLC26A3 exspression level in the tumoral area showed a statistical 
significative reduction (about 36%) eventhough no SLC26A3 reduction 
was observed in 6/27 paired samples. Moreover, the standard deviation 
values observed for both non-tumoral (N) and tumoral (T) groups clearly 
indicate a great inter-individual variability among the specimens 
analyzed. Regarding the Clinicopathological characteristics of the gastric 
cancer patients (Table 2), it appeared that there was no correlation among 
tumor type and SLC26A3 down-regulation neverthless, we can postulate 
that the low SLC26A3 expression might appear in an advanced tumor 
stage and thus correlated to the tumor prognosis. However, to better 
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underline the clinical importance of the observed SLC26A3 reduction, a 
larger population of gastric cancer patients should be analyzed. 
 
Conclusion 
In conclusion, although we have shown for the first time the presence of 
GKN1 mRNA in human serum of healthy subjects as well as in that of 
patients with diagnosis of gastric cancer, when we analyzed by qRT-PCR 
these sera, we did not observe significant statistical differences among the 
two population. Therefore, we could not confirm our hypothesis that 
serum GKN1 mRNA could serve as non-invasive marker for GC. 
Moreover, our results suggested that SLC26A3, a new molecular 
interactor of GKN1, seems to be a potential biomarker of cell 
tansformation since it was down-regulated during tumor progression both 
at protein and mRNA levels. Therefore, evaluation of SLC26A3 in human 
sera might end-up as a successful potential GC biomarker. 
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